S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
Outcome of adults with acute lymphocytic leukemia after second salvage therapy
Susan O'Brien,Deborah A. Thomas,Farhad Ravandi,Stefan Faderl,Jorge E. Cortes,G. Borthakur,Sherry Pierce,Guillermo Garcia-Manero,Hagop M. Kantarjian +8 more
TL;DR: The objectives of the current study were to predict outcomes and determine the prognostic factors associated with second salvage therapy in patients with ALL, and to predict investigational approaches aimed at helping this subset of patients.
Journal ArticleDOI
Phase II study of alemtuzumab in chronic lymphoproliferative disorders
Alessandra Ferrajoli,Susan O'Brien,Jorge E. Cortes,Francis J. Giles,Deborah A. Thomas,Stefan Faderl,Razelle Kurzrock,Susan Lerner,Dimitrios P. Kontoyiannis,Michael J. Keating +9 more
TL;DR: The authors conducted a Phase II trial to evaluate the efficacy and safety of alemtuzumab in advanced or refractory chronic lymphoproliferative disorders.
Journal ArticleDOI
Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia
William G. Wierda,Susan O'Brien,Xuemei Wang,Stefan Faderl,Alessandra Ferrajoli,Kim Anh Do,Guillermo Garcia-Manero,Jorge E. Cortes,Deborah A. Thomas,Charles Koller,Jan A. Burger,Susan Lerner,Ellen J. Schlette,Lynne V. Abruzzo,Hagop M. Kantarjian,Michael J. Keating +15 more
TL;DR: A multivariable model that incorporates traditional and newer prognostic factors to identify patients at high risk for progression to treatment is developed and may be useful to identify Patients for early interventional trials.
Journal Article
Imatinib Mesylate for Philadelphia Chromosome-positive, Chronic-Phase Myeloid Leukemia after Failure of Interferon-α Follow-Up Results
Hagop M. Kantarjian,Moshe Talpaz,Susan O'Brien,Terry L. Smith,Francis J. Giles,Stefan Faderl,Deborah A. Thomas,Guillermo Garcia-Manero,Jean Pierre J. Issa,Michael Andreeff,Steven M. Kornblau,Charles Koller,Milosav Beran,Michael J. Keating,Mary Beth Rios,Jenny Shan,Debra Resta,Renaud Capdeville,Kimberly Hayes,Maher Albitar,Emil J. Freireich,Jorge E. Cortes +21 more
TL;DR: Imatinib mesylate is highly effective in chronic-phase CML after IFN-alpha failure and pretreatment and treatment-associated factors that were associated with higher major cytogenetic response rates and with improved survival are identified.
Journal ArticleDOI
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy
Alfonso Quintás-Cardama,Hagop M. Kantarjian,Guillermo Garcia-Manero,Susan O'Brien,Stefan Faderl,Zeev Estrov,Francis J. Giles,Anthony J. Murgo,Nakia Ladie,Srdan Verstovsek,Jorge E. Cortes +10 more
TL;DR: Homoharringtonine is a cephalotaxus alkaloid that inhibits the synthesis of proteins leading to apoptosis that has demonstrated activity in patients with chronic myeloid leukemia after failure with interferon.